Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

IMMUNOTHERAPY

Zooming in on dendritic cells for CD40 agonists

Nature Cancer volume 3, pages 268–269 (2022)Cite this article

Subjects

Severe side effects limit the therapeutic potential of checkpoint control and immunomodulatory antibodies in immunotherapy of cancer. A new study demonstrates that bispecific antibodies directing the immunostimulatory activity of CD40-specific antibodies on dendritic cell subsets may allow a greater therapeutic window of opportunity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Enhancing activation of tumor-specific T cells via bispecific antibodies targeting CD40 on dendritic cells.

References

  1. Ribas, A. & Wolchok, J. D. Science 359, 1350–1355 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Vonderheide, R. H. Annu. Rev. Med. 71, 47–58 (2020).

    Article  CAS  PubMed  Google Scholar 

  3. Remer, M., White, A., Glennie, M., Al‐Shamkhani, A. & Johnson, P. Curr. Top Microbiol. Immunol. 405, 165–207 (2017).

    CAS  PubMed  Google Scholar 

  4. Li, F. & Ravetch, J. V. Science 333, 1030–1034 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. White, A. L. et al. J. Immunol. 187, 1754–1763 (2011).

    Article  CAS  PubMed  Google Scholar 

  6. White, A. L. et al. J. Immunol. 193, 1828–1835 (2014).

    Article  CAS  PubMed  Google Scholar 

  7. Yu, X. et al. Cancer Cell 37, 850–866 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yu, X. et al. Cancer Cell 33, 664–675 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Dahan, R. et al. Cancer Cell 29, 820–831 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Knorr, D. A., Dahan, R. & Ravetch, J. V. Proc. Natl Acad. Sci. USA 115, 11048–11053 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Irenaeus, S. M. M. et al. Int. J. Cancer 145, 1189–1199 (2019).

    Article  CAS  PubMed  Google Scholar 

  12. Garris, C. S., Wong, J. L., Ravetch, J. V. & Knorr, D. A. Sci. Transl. Med. 13, eabd1346 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Salomon, R. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00329-6 (2022).

  14. Baeuerle, P. A., Kufer, P. & Bargou, R. Curr. Opin. Mol. Ther. 11, 22–30 (2009).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Genetics, Department of Biology, University of Erlangen-Nürnberg, Erlangen, Germany

    Julian Hübner & Falk Nimmerjahn

Authors
  1. Julian Hübner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Falk Nimmerjahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Falk Nimmerjahn.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hübner, J., Nimmerjahn, F. Zooming in on dendritic cells for CD40 agonists. Nat Cancer 3, 268–269 (2022). https://doi.org/10.1038/s43018-022-00340-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00340-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer